参考文献/References:
[1] Vilar L,Vilar CF,Lyra R,et al. Pitfalls in the diagnostic evaluation of hyperprolactinemia[J].Neuroendocrinology,2019,109(1):7-19.DOI:10.1159/000499694.
[2] Galland F,Vantyghem MC,Cazabat L,et al. Management of nonfunctioning pituitary incidentaloma[J].Ann Endocrinol(Paris),2015,76(3):191-200.DOI:10.1016/j.ando.2015.04.004.
[3] Saleem M,Martin H,Coates P. Prolactin biology and laboratory measurement:an update on physiology and current analytical issues[J].Clin Biochem Rev,2018,39(1):3-16.
[4] Che Soh NAA,Yaacob NM,Omar J,et al. Global prevalence of macroprolactinemia among patients with hyperprolactinemia:a systematic review and meta-analysis[J].Int J Environ Res Public Health,2020,17(21):8199.DOI:10.3390/ijerph17218199.
[5] Kalsi AK,Halder A,Jain M,et al. Prevalence and reproductive manifestations of macroprolactinemia[J].Endocrine,2019,63(2):332-340.DOI:10.1007/s12020-018-1770-6.
[6] Zygourakis CC,Imber BS,Chen R,et al. Cost-effectiveness analysis of surgical versus medical treatment of prolactinomas[J].J Neurol Surg B Skull Base,2017,78(2):125-131.DOI:10.1055/s-0036-1592193.
[7] Ananthakrishnan S. The dark side to dopamine agonist therapy in rolactinoma management[J].Endocr Pract,2017,3(4):e384-e386.DOI:10.4158/EP161709.CO.
[8] Tran T,Brophy JM,Suissa S,et al. Risks of cardiac valve regurgitation and heart failure associated with ergot- and non-ergot-derived dopamine agonist use in patients with Parkinson's disease:a systematic review of observational studies[J].CNS drugs,2015,29(12):985-998.DOI:10.1007/s40263-015-0293-4.
[9] Dogansen SC,Cikrikcili U,Oruk G,et al. Dopamine agonist-induced impulse control disorders in patients with prolactinoma:a cross-sectional multicenter study[J].J Clin Endocrinol Metab,2019,104(7):2527-2534.DOI:10.1210/jc.2018-02202.
[10] Honegger J,Nasi-Kordhishti I,Aboutaha N,et al. Surgery for prolactinomas:a better choice?[J].Pituitary,2020,23(1):45-51.DOI:10.1007/s11102-019-01016-z.
[11] McDonald RJ,Levine D,Weinreb J,et al. Gadolinium retention:a research roadmap from the 2018 NIH/ACR/RSNA workshop on gadolinium chelates[J].Radiology,2018,289(2):517-534.DOI:10.1148/radiol.2018181151.
[12] asanueva FF,Molitch ME,Schlechte JA,et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas[J].Clin Endocrinol(Oxf),2006,65(2):265-273.DOI:10.1111/j.1365-2265.2006.02562.x.
[13] Melmed S,Casanueva FF,Hoffman AR,et al. Diagnosis and treatment of hyperprolactinemia:an Endocrine Society Clinical practice guideline[J].J Clin Endocrinol Metab,2011,96(2):273-288.DOI:10.1210/jc.2010-1692.
[14] Samson SL,Hamrahian AH,Ezzat S. American Association of Clinical Endocrinologists,American College of Endocrinology Diseasa State clinical review:clinical relevance of macroprolactin in the absence or presence of true hyperprolactinemia[J].Endocr Pract,2015,21(12):1427-1435.DOI:10.4158/EP15938.DSC.
[15] Fahie-Wilson M,Smith TP. Determination of prolactin:the macroprolactin problem[J].Best Pract Res Clin Endocrinol Metab,2013,27(5):725-742.DOI:10.1016/j.beem.2013.07.002.
[16] Sheta SM,El-Sheikh SM,Abd-Elzaher MM. A novel optical approach for determination of prolactin based on Pr-MOF nanofibers[J].Anal Bioanal Chem,2019,411(7):1339-1349.DOI:10.1007/s00216-018-01564-6.
[17] Duong-Ly KC,Gabelli SB. Gel filtration chromatography(size exclusion chromatography)of proteins[J].Methods Enzymol,2014,541:105-114.DOI:10.1016/B978-0-12-420119-4.00009-4.
[18] Bell DA,Hoad K,Leong L,et al. A high pressure liquid chromatography method for separation of prolactin forms[J].Ann Clin Biochem,2012,49(Pt 3):285-288.DOI:10.1258/acb.2011.011209.
[19] Chen Y,Wang H,Yang W,et al. A new method of using polyethylene glycol(PEG)precipitation of macroprolactin to detect genuine hyperprolactinemia[J].J Clin Lab Anal,2016,30(6):1169-1174.DOI:10.1002/jcla.21999.
[20] 杨青青,张晓梅,李辉,等.高泌乳素血症中巨泌乳素筛查方法的研究[J].蚌埠医学院学报,2019,44(1):36-38.DOI:10.13898 /j.cnki.issn.1000-2200.2019.01.009.
[21] Smith T,Stern E,Tan E,et al. Macroprolactinemia detection by magnetically assisted polyethylene glycol precipitation:potential for automation[J].J Appl Lab Med,2020,5(3):494-505.DOI:10.1093/jalm/jfaa015.
[22] Jimenez-Anon L,Barallat J,Regidor D,et al. Assessment of intraindividual agreement in prolactin results after post-polyethylene glycol precipitation test for the estimation of macroprolactin. Should the precipitation procedure be repeated in the same patient?[J].Clin Chem Lab Med,2020,59(1):e27-e29.DOI:10.1515/cclm-2020-0858.
[23] Smith TP,Fahie-Wilson MN. Reporting of post-PEG prolactin concentrations:time to change[J].Clin Chem,2010,56(3):484-485.DOI:10.1373/clinchem.2009.135210.
[24] Kasum M,Oreskovic S,Zec I,et al. Macroprolactinemia:new insights in hyperprolactinemia[J].Biochem Med(Zagreb),2012,22(2):171-179.DOI:10.11613/bm.2012.020.
[25] Sapin R,Kertesz G. Macroprolactin detection by precipitation with protein A-sepharose:a rapid screening method compared with polyethylene glycol precipitation[J].Clin Chem,2003,49(3):502-505.DOI:10.1373/49.3.502.
[26] Beda-Maluga K,Pisarek H,Romanowska I,et al. Ultrafiltration-an alternative method to polyethylene glycol precipitation for macroprolactin detection[J].Arch Med Sci,2015,11(5):1001-1007.DOI:10.5114/aoms.2015.54854.